Lind announces Advisory Board
Lind announced the formation of its Advisory Board, bringing together leaders across oncology, clinical research, health-system operations, and AI to guide the company as it scales clinician-guided trial screening across health systems.
By Lind Team
Lind today announced the formation of its Advisory Board, assembling leaders across oncology, clinical research, health-system operations, and artificial intelligence to support the company’s next phase of growth. The Advisory Board will be composed of Dr. Richard Schilsky, Amy Chang and Thomas Stanis. This esteemed board will advise on clinical strategy, evidence generation, responsible AI deployment, and health-system adoption as Lind expands its trial-screening platform nationally and internationally.
Dr. Schilsky served as Chief Medical Officer and Executive Vice President of the American Society of Clinical Oncology (ASCO) — the world’s largest professional organization for physicians and oncology professionals. During his tenure, he oversaw ASCO’s clinical affairs, guidelines, and quality programs, and played a central role in shaping oncology research policy. Prior to ASCO, Dr. Schilsky was Chief of Hematology/Oncology at the University of Chicago and served in leadership roles at the National Cancer Institute, including as chair of the Cancer and Leukemia Group B (CALGB). He is widely recognized as one of the foremost voices in clinical trial design, conduct, and policy
Amy Chang serves on the boards of directors of Salesforce, Procter & Gamble, and The Walt Disney Company. She previously founded Accompany, an AI-driven relationship intelligence platform, which was acquired by Cisco in 2018, where she then served as SVP leading Cisco’s Collaboration business unit. Chang brings deep expertise in AI product strategy, enterprise go-to-market, and scaling technology businesses. Her experience building AI-native products and operating at board level across three of the world’s largest companies provides Lind with strategic guidance on enterprise sales, product-market fit, and organizational scaling.
Thomas Stanis served as CTO of Verily (formerly Google Life Sciences) and as VP of Engineering at Google. At Verily, he led the technical organization building health data platforms, clinical research tools, and regulatory-grade software for life sciences. His experience is directly relevant to Lind’s core challenge: building clinical-grade AI infrastructure that integrates with health system workflows. From HIPAA-compliant data pipelines to FDA-adjacent software quality, Stanis has navigated the technical and regulatory landscape that Lind operates in.
“Building trustworthy AI for cancer care requires the best minds in oncology, scaling technology and clinical research at the table. This Advisory Board brings exactly that expertise as we scale,” said Oggie Nikolic, CEO and Founder of Lind.